Succinoglycan riclin relieves UVB-induced skin injury with anti-oxidant and anti-inflammatory properties.

Excessive UVB exposure increases the production of reactive oxygen species (ROS), which causes oxidative damage and epidermal inflammation. Previous studies have identified that the succinoglycan riclin has potent anti-inflammatory properties. The current study aims to investigate whether riclin protects against UVB-induced photodamage. In vitro, riclin demonstrated excellent moisture-preserving properties, along with antioxidant potential by scavenging superoxide anions, hydroxyl and DPPH radicals. Riclin increased Col1α1 and Col3α1 expression in NIH3T3 cells, inhibited oxidation and melanin synthesis by B16F10 cells upon UVB irradiation. In vivo, topical application of riclin effectively attenuated UVB-induced skin damage in C57BL6 mice, which was characterized by erythema, epidermal hyperplasia, hydroxyproline loss and ROS production in skin tissue. Riclin suppressed skin inflammation by the elevation of TNF-α, IL-6, IL-β, and alleviated UVB-induced immune cell up-regulation. Moreover, treatment with a Dectin-1 inhibitor reversed the protective effect of riclin in THP-1 cells. • A succinoglycan riclin displayed significant moisturizing and free radical scavenging activity. • Riclin attenuated UVB-induced skin damage in vivo. • Riclin promoted collagen levels and decreased the synthesis of melanin • Riclin exerts anti-photoaging properties via Dectin-1 signaling pathway. [ABSTRACT FROM AUTHOR]